Edesa Biotech (EDSA) Cash & Equivalents (2013 - 2026)

Edesa Biotech has reported Cash & Equivalents for 13 years, with the latest figure at $12.1 million in Q4 2025.

• Quarterly Cash & Equivalents rose 670.82% year-over-year to $12.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.1 million (up 670.82% YoY) and the FY2025 annual result came in at $10.8 million, up 940.39% from the prior year.
• Cash & Equivalents rose to $12.1 million in Q4 2025 per EDSA's latest filing, from $10.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $15.9 million in Q1 2022 and troughed at $1.0 million in Q3 2024.
• A 5-year average of $7.8 million and a median of $7.7 million in 2021 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents sank 80.65% in 2024, then jumped 940.39% in 2025.
• Over 5 years, Cash & Equivalents stood at $5.9 million in 2021, then surged by 40.63% to $8.3 million in 2022, then slumped by 48.4% to $4.3 million in 2023, then slumped by 63.37% to $1.6 million in 2024, then jumped by 670.82% to $12.1 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $12.1 million, $10.8 million, and $12.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.